Lupus Nephritis Market Report 2034: Epidemiology, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight

Lupus Nephritis companies are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, and others.

LAS VEGAS, NEVADA, UNITED STATES, June 13, 2024 /EINPresswire.com/ -- DelveInsight’s “Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Recent breakthroughs in the Lupus Nephritis Market:

ATA3219: The investigational new drug, ATA3219, has received FDA approval for the treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis). The approval was granted for study, and the first trial participants are expected to be enrolled in the second half of 2024.
(In 2020) Benlysta^®: The FDA approved Benlysta^® to treat lupus nephritis (lupus-related kidney disease) in adults. This approval covers both the intravenous and subcutaneous formulations. Benlysta is the first lupus therapy authorized to treat this potentially life-threatening complication of the disease.
(In 2024) CB-010: The FDA has granted approval for a Phase 1 study to evaluate the safety and efficacy of investigational therapy, CB-010, for the treatment of lupus nephritis (LN). The GALLOP study will begin by year-end and will also be evaluated for people with extra renal lupus (when LN symptoms affect other parts of the body).

To Know in detail about the Lupus Nephritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lupus Nephritis Market Forecast

Some of the key facts of the Lupus Nephritis Market Report:

The Lupus Nephritis market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
The market size for Liver Fibrosis (NASH) in the 7MM was valued at USD 2,225 million in 2021.
The United States held the largest share of the Liver Fibrosis (NASH) Market, contributing approximately 79% of the total market size in the 7MM in 2021, when compared to other significant markets such as the EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Among the EU5 countries, Germany boasted the highest market size for Liver Fibrosis, with USD 94 million in 2021, whereas Spain had the smallest market size for Liver Fibrosis (NASH), with USD 55 million in 2021.
The market size for Liver Fibrosis (NASH) in Japan was estimated at USD 108 Million in 2021, representing 5% of the total 7MM market.
The anticipated introduction of new therapies, including Resmetirom, Lanifibranor, Aramchol, and others, is expected to bring about changes in the total market for Liver Fibrosis (NASH) in the coming years.
Key Lupus Nephritis Companies: Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, and others
Key Lupus Nephritis Therapies: LUPKYNIS (voclosporin), BENLYSTA (belimumab), Ianalumab (VAY736), SAPHNELO (anifrolumab), and others
The Lupus Nephritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lupus Nephritis pipeline products will significantly revolutionize the Lupus Nephritis market dynamics.

Lupus Nephritis Overview

Lupus nephritis is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system mistakenly attacks its own tissues. This kidney inflammation can impair the kidneys' ability to remove waste and excess fluids from the blood, leading to serious health issues.

Lupus Nephritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
In 2023, there were approximately 660,000 diagnosed cases of SLE (systemic lupus erythematosus) across the 7MM (seven major markets), with this number expected to rise during the forecast period.
The United States had the highest prevalence of lupus nephritis, making up about 50% of the total cases in the 7MM. The EU4 (Germany, France, Italy, and Spain) along with the UK, and Japan accounted for around 36% and 14% of the total population share, respectively.
Specifically, the United States had nearly 130,000 diagnosed cases of lupus nephritis in 2023.
Within the EU4 and the UK, the UK had the highest number of lupus nephritis cases, followed by Germany, while France had the lowest number of cases in 2023.

Lupus Nephritis Epidemiology Segmentation:

The Lupus Nephritis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Lupus Nephritis
Prevalent Cases of Lupus Nephritis by severity
Gender-specific Prevalence of Lupus Nephritis
Diagnosed Cases of Episodic and Chronic Lupus Nephritis

Download the report to understand which factors are driving Lupus Nephritis epidemiology trends @ Lupus Nephritis Epidemiology Forecast

Lupus Nephritis Marketed Drugs

LUPKYNIS (voclosporin): Aurinia Pharmaceuticals/Otsuka Pharmaceuticals
BENLYSTA (belimumab): GlaxoSmithKline
Lupus Nephritis Emerging Drugs
Ianalumab (VAY736): Novartis/MorphoSys
SAPHNELO (anifrolumab): AstraZeneca

Lupus Nephritis Drugs Insights

The optimal treatment for lupus nephritis depends on the classification of the morphological findings in a kidney biopsy. Typically, a combination of corticosteroids and immunosuppressants is used to manage the condition. Common immunosuppressive medications include cyclophosphamide, mycophenolate mofetil, azathioprine, and calcineurin inhibitors.

As of now, there are only two FDA-approved medications specifically for lupus nephritis. BENLYSTA (belimumab) was approved in December 2020 for adults and in July 2022 for children aged 5–17 with active lupus nephritis. It is available in both intravenous (IV) infusion and subcutaneous injection forms. LUPKYNIS (voclosporin), approved in January 2021, is the first oral treatment for lupus nephritis, representing a significant milestone for those with lupus-related kidney disease.

Monoclonal antibodies (mAbs) are a relatively new class of drugs for lupus treatment. These biologics are produced in a lab using living cells as biological “factories.” They have been successfully used for years in treating certain cancers and autoimmune diseases like rheumatoid arthritis and Crohn’s disease, and more recently, for lupus. Monoclonal antibodies offer a different approach by targeting specific cells or chemicals that cause lupus symptoms, rather than just limiting the symptoms themselves.

Lupus Nephritis Therapies

Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis

Lupus Nephritis Therapies

LUPKYNIS (voclosporin), BENLYSTA (belimumab), Ianalumab (VAY736), SAPHNELO (anifrolumab)

Discover more about therapies set to grab major Lupus Nephritis market share @ Lupus Nephritis Treatment Landscape

Lupus Nephritis Market Outlook

Mycophenolate mofetil (MMF) and cyclophosphamide (CYC) are among the most common treatments for lupus nephritis. The gold-standard regimen typically includes MMF, corticosteroids, and CYC. Corticosteroids have long been a cornerstone in managing lupus nephritis, effectively controlling renal flares but not significantly improving long-term outcomes when used alone. Currently, Rituximab is the most commonly used monoclonal antibody (mAb) for lupus nephritis.

There are only two FDA-approved medications specifically for lupus nephritis: BENLYSTA (belimumab), available as an intravenous (IV) infusion or subcutaneous (SC) injection, and LUPKYNIS (voclosporin), a novel oral calcineurin inhibitor.

Scope of the Lupus Nephritis Market Report:

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Lupus Nephritis Companies: Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, and others
Key Lupus Nephritis Therapies: LUPKYNIS (voclosporin), BENLYSTA (belimumab), Ianalumab (VAY736), SAPHNELO (anifrolumab), and others
Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Lupus Nephritis Unmet Needs, KOL’s views, Analyst’s views, Lupus Nephritis Market Access and Reimbursement

Table of Contents:

1. Lupus Nephritis Market Report Introduction
2. Executive Summary for Lupus Nephritis
3. SWOT analysis of Lupus Nephritis
4. Lupus Nephritis Patient Share (%) Overview at a Glance
5. Lupus Nephritis Market Overview at a Glance
6. Lupus Nephritis Disease Background and Overview
7. Lupus Nephritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Lupus Nephritis
9. Lupus Nephritis Current Treatment and Medical Practices
10. Lupus Nephritis Unmet Needs
11. Lupus Nephritis Emerging Therapies
12. Lupus Nephritis Market Outlook
13. Country-Wise Lupus Nephritis Market Analysis (2020–2034)
14. Lupus Nephritis Market Access and Reimbursement of Therapies
15. Lupus Nephritis Market Drivers
16. Lupus Nephritis Market Barriers
17. Lupus Nephritis Appendix
18. Lupus Nephritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Lupus Nephritis Pipeline

"Lupus Nephritis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Lupus Nephritis market. A detailed picture of the Lupus Nephritis pipeline landscape is provided, which includes the disease overview and Lupus Nephritis treatment guidelines.

Lupus Nephritis Epidemiology

DelveInsight's 'Lupus Nephritis Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Lupus Nephritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani
DelveInsight Business Research LLP
+1 469-945-7679
email us here